⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PVLA News
Palvella Therapeutics, Inc. Common Stock
Palvella Therapeutics Announces Pricing of Upsized Public Offering
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Announces Proposed Public Offering
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
globenewswire.com
PVLA
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
globenewswire.com
PVLA
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
globenewswire.com
PVLA
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
globenewswire.com
PVLA
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
globenewswire.com
PVLA